OMICS Group Conferences
Accelerating Scientific Discovery

2nd World Congress on
Cancer Science & Therapy

September 10-12, 2012 Hilton San Antonio Airport, USA

Percutaneous cryoablation and 125I seeds implantation combined with chemotherapy for the treatment of advanced pancreatic cancer: Reports of 96 cases

Lizhi Niu
Fuda Cancer Cryotherapy Research Institute, China

To assess the efficacy and the safety of percutaneous cryoablation (PCC) and ^{125}I seeds implantation combined with chemotherapy in the treatment of advanced pancreatic cancer, ninety six patients (male 58, average age 56.9) with advanced pancreatic cancer (55 with pancreatic head cancer, 80 in stage IV) underwent PCC and I125 seeds implantation combined with concomitant chemotherapy (gemcitabine hydrochloride and DDP) were analyzed. One hundred and seventeen percutaneous procedures of cryosurgeries combined I125 seeds implantation were performed. Clinical benefit response (CBR), therapy-related complications, postcryoablative CT imaging and survival rate were assessed. Eighty seven patients were followed up successfully. Median survival was 10.5, and 6-month and 1-year survival was 69.6% (stage III vs. IV, 66.7% vs. 71.4%) and 43.1% (stage III vs. IV, 50.0% vs. 40.1%), respectively. The maximum survival reached 47 months. CR, PR and SD were achieved in 9, 26 and 53 patients, respectively. Sixty eight and 63 in 79 patients experienced a ≥50% reduction of pain score and analgesic consumption, respectively, 26 patients experienced a ≥2kg weight gaining, and average KPS increased significantly ($P<0.05$). No serious therapy-related complications except pancreatic fistula accompanied abdominal hemorrhage, bile leakage, acute pancreatitis and ^{125}I seeds leaved over in needle track occurred in 1, 1, 2 and 1 case, respectively. PCC and ^{125}I seeds implantation combined with chemotherapy are effective and safe for the treatment of advanced pancreatic cancer.

Biography

Upon completion of his doctorate in Thoracic Surgery at The Fourth Military Medical University in 1996 he directed clinical research on surgical treatment of thoracic disease at The First Military Medical University affiliated Nanfang Hospital. From 2002, he launched out into research on minimally invasive therapy of cancer treatment, especially cryosurgery, when he work in Guangzhou Fuda Cancer Hospital. Upon experience of more than 6000 cases of cryosurgeries on various tumors, including lung cancer, pancreatic cancer, liver cancer, prostate cancer, kidney cancer, esophagus cancer, stomach cancer, intestinal cancer, thyroid carcinoma and so on, he carried out a Comprehensive study of crysurgery on lung cancer, completed over 2000 cryosurgeries on lung cancer and reported his successful experience on cryotherapy for the treatment of lung cancer, especially advanced lung cancer. and was awarded “Brilliant contribution to World Conference on Interventional Oncology” on the 14th World Congress of Cryosurgery in Beijing (2007), Presidental Award at the 36th Janpan Annual Meeting of Low Temperature Medicine, Tokyo, Japan (2009), Outstanding Contributioner to Chinese Cryosurgery at World Cancer Congress (2010) and Gold Medel and Book Award (Cryosurgery for Cancer, 2007, in chinese) of International Society of Cryosurgery 16th World Congress in Vienna (2011).

quincyhe@163.com